Caution in interpreting biochemical control rates after treatment for prostate cancer: Length of follow-up influences results

Urology

Volumn 54, Issue 5, 1999, Pages 875-879

  Connell, Philip P ^a   Ignacio, Lani ^a   McBride, Russell B ^a   Weichselbaum, Ralph R ^a   Vijayakumar, Srinivasan ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; ARTICLE; CANCER RADIOTHERAPY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER;

ACTUARIAL ANALYSIS; FOLLOW-UP STUDIES; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 0032729399     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00253-8     Document Type: Article

References (29)

1. Oesterling J.E. Prostate specific antigen a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate . J Urol. 145:1991;907-923.
2. Zietman A.L., Tibbs M.K., Dallow K.C., et al. Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate. Radiother Oncol. 40:1996;159-162.
3. Zagars G.K., von Eschenbach A.C. Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapy. Cancer. 72:1993;538-548.
4. Zagars G.K. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy. J Urol. 152:1994;1786-1791.
5. Zelefsky M.J., Leibel S.A., Wallner K.E., et al. Significance of normal serum prostate-specific antigen in the follow-up period after definitive radiation therapy for prostatic cancer. J Clin Oncol. 13:1995;459-463.
6. Sartor C.I., Strawderman M.H., Lin X.H., et al. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int J Radiat Oncol Biol Phys. 38:1997;941-947.
7. Hanks G.E., D'Amico A., Epstein B.E., et al. Prostatic-specific antigen doubling times in patients with prostate cancer a potentially useful reflection of tumor doubling time . Int J Radiat Oncol Biol Phys. 27:1993;125-127.
8. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 280:1998;969-974.
9. Kupelian P., Katcher J., Levin H., et al. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores . Cancer J Sci Am. 3:1997;78-87.
10. D'Amico A.V., Whittington R., Kaplan I., et al. Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of >4-20 ng/ml. Int J Radiat Oncol Biol Phys. 37:1997;1053-1058.
11. Polascik T.J., Pound C.R., DeWeese T.L., et al. Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer a 7-year biochemical (PSA) progression analysis . Urology. 51:1998;884-890.
12. Consensus statement guidelines for PSA following radiation therapy . Int J Radiat Oncol Biol Phys. 37:1997;1035-1041.
13. Hanks G.E., Hanlon A.L., Schultheiss T.E., et al. Dose escalation with 3D conformal treatment five year outcomes, treatment optimization, and future directions . Int J Radiat Oncol Biol Phys. 41:1998;501-510.
14. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 41:1998;491-500.
15. Leibel S.A., Zelefsky M.J., Kutcher G.J., et al. Three-dimensional conformal radiation therapy in localized carcinoma of the prostate interim report of a phase 1 dose-escalation study . J Urol. 152:1994;1792-1798.
16. Vijayakumar S., Low N., Chen G.T., et al. Beams eye view-based photon radiotherapy. Int J Radiat Oncol Biol Phys. 21:1991;1575-1586.
17. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
18. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 50:1966;163-170.
19. Michalaski J.M., Purdy J.A., Winter K., et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406 (abstract). Int J Radiat Oncol Biol Phys. 42:1998;142.
20. Sandler H.M., Perez-Tamayo C., Ten Haken R.K., et al. Dose escalation for stage C (T3) prostate cancer minimal rectal toxicity observed using conformal therapy . Radiother Oncol. 23:1992;53-54.
21. Pinover W.H., Hanlon A.L., Horwitz E.M., et al. Defining the appropriate dose for prostate cancer patients with PSA <10 ng/ml (abstract). Int J Radiat Oncol Biol Phys. 42:1998;142.
22. Fiveash J.B., Hanks G.E., Roach M. III, et al. 3D conformal radiation therapy (3DCRT) for high grade prostate cancer a multi-institutional review (abstract) . Int J Radiat Oncol Biol Phys. 42:1998;143.
23. Hanks G.E., Hanlon A.L., Horwitz E., et al. A relationship of local prostate dose and subsequent metastasis with 3D CRT in prostate cancer (abstract). Int J Radiat Oncol Biol Phys. 42:1998;143.
24. Wurzer J.C., Hanlon A., Horwitz E., et al. Analysis of bNED control and factors predicting outcome in non-palpable (clinical stage T1C) adenocarcinoma of the prostate treated with 3D conformal external beam radiation therapy (abstract). Int J Radiat Oncol Biol Phys. 42:1998;144.
25. Shipley W.U., Verhey L.J., Munzenrider J.E., et al. Advanced prostate cancer the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone . Int J Radiat Oncol Biol Phys. 32:1995;3-12.
26. Forman J.D., Duclos M., Shamsa F., et al. Hyperfractionated conformal radiotherapy in locally advanced prostate cancer results of a dose escalation study . Int J Radiat Oncol Biol Phys. 34:1996;655-662.
27. Pollack A., Zagars G.K., Starkschall G., et al. Conventional vs. conformal radiotherapy for prostate cancer preliminary results of dosimetry and acute toxicity . Int J Radiat Oncol Biol Phys. 34:1996;555-564.
28. Pisansky T.M., Kahn M.J., Rasp G.M., et al. A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma. Cancer. 79:1997;337-344.
29. Vijayakumar S: Fine tuning the definition of biochemical failure after radiation therapy (RT) in prostate cancer (PC): use of a quadratic curve to determine nadir PSA value. Presented at the Annual Meeting of the American Radium Society, Monte Carlo, Monaco, May 3-6, 1998.